Alkermes
artistry dose expansion cohort case study year old male cutaneous melanoma patient diagnosis melanoma diagnosed on study activity started remains on treatment prior treatment line therapy vaccine change in target lesion from duration mos best response cycle cycle target lesion size stable disease reduction partial response reduction treatment related aes last dose of prior treatment manageable with no dose modifications anemia and fever grade intermittent grade and grade patient continues on therapy as of march per criteria reported after the data cut off and awaiting confirmation progressive disease stable disease data cut off march | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
68 of 144
Similar slides by Alkermes
See diffirences between slides (animation)
Investor Day
March 2021
artistry in combination with case study year old female with high grade serous diagnosis on study activity high grade serous diagnosed status positive status negative status low prior treatment line therapy duration mos best response pac started remains on treatment subcutaneous change in target lesion and levels from total target lesions size cycle reduction partial response treatment related aes level unit reduction manageable with no known dose modifications last dose of prior treatment hypotension and dehydration grade and multiple events patient continued on therapy as of march per criteria awaiting confirmation progressive disease partial response platinum resistant ovarian cancer tumor mutational burden homologous recombination deficiency pac multiple injection site reactions grade data as of march | Alkermes
Investor Day
March 2021
artistry in combination with case study year old ovarian cancer patient artistry part efficacy diagnosis on study tumor shrinkage high grade serous ovarian cancer status unknown status wild type platinum resistant prior treatment change in target lesions from cycle stable disease reduction cycle stable disease reduction cycle stable disease reduction line therapy duration mos best response cycle partial response reduction last dose not evaluable patient has remained on treatment for months treatment related aes manageable with no dose modifications majority aes grade and grade elevated alt and grade anemia notes continues on therapy as of march per criteria reported after the data cut off and awaiting confirmation progressive disease partial response stable disease data cut off march | Alkermes
Related slides by other companies
ModivCare
Investor Presentation
January 2021
new leadership with a track record of operational excellence | ModivCare
Yellow Corporation
Investor Presentation
September 2016
forward looking considerations | Yellow Corporation
Cano Health
Investor Day
June 2022
health national presence | Cano Health
Yellow Corporation
Investor Presentation
May 2016
forward looking considerations | Yellow Corporation
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io